Latest News: Proscia Receives FDA 510(k) Clearance For Concentriq AP-DxREAD THE PRESS RELEASE

Proscia expands into international digital pathology market to help with rising cancer burden

Proscia
By Author Proscia | February 20, 2020

Proscia, a leading provider of artificial intelligence (AI) enabled digital pathology solutions, has expanded into the international diagnostic pathology market to meet the growing needs of laboratories and cancer patients worldwide. The company has added the leadership of Arun Ananthapadmanabhan as Executive Vice President, Global Growth, to manage commercial operations for its international market. Proscia’s accelerated global focus follows the company’s November announcement that it received CE Mark for its Concentriq Dx solution for use in primary diagnosis.

Our website uses cookies. By using this site, you agree to its use of cookies.